Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Cmir Dana Farber topic
No spam. Unsubscribe anytime.
Health Policy Commission releases final report on Dana Farber–BIDMC affiliation, urges continued monitoring
Summary
The Health Policy Commission voted to publish its final cost and market impact review of the proposed Dana Farber–BIDMC–HMFP affiliation, finding likely inpatient savings but potential outpatient spending increases and urging DPH and the attorney general to use their authorities to monitor price growth.
The Health Policy Commission voted to release its final cost and market impact review of the proposed clinical affiliation between Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center and Harvard Medical Faculty Physicians, beginning the statutorily required review window for other state regulators.
The final report concludes the affiliation is likely to shift inpatient oncology care to a new Dana Farber hospital and produce modest inpatient spending savings, but staff said outpatient spending could rise because Dana Farber’s commercial outpatient prices are substantially higher. Executive Director David Seltz told commissioners the commission’s role was to “bring transparency to the public” and to equip regulators and policymakers with evidence, not to approve or block the transaction.
Staff described a range of quantified impacts: estimated annual commercial inpatient savings in a roughly $18.5–$23 million range (plus additional identified savings of $3.5–$5.3 million in related areas) and outpatient repricing effects that could raise commercial outpatient spending (staff estimated about $31.7 million tied to oncology drugs, infusion services and related outpatient care if services transition at Dana Farber prices). Staff also noted possible Medicare effects and said future price growth at Dana Farber could erode any savings.
The report addressed quality and access. Staff said they did not identify a decline in clinical quality from the affiliation but warned of potential short‑term disruptions that would require robust care coordination planning. On access, staff concluded available information did not clearly show whether the affiliation is necessary or sufficient to meet future inpatient access needs without additional planning.
Sasha, a staff presenter, summarized commitments Dana Farber made in response to the preliminary report: confidential price reporting to HPC for five years after the hospital opens, confidential reporting on outpatient oncology drug pricing, and public reporting on community‑care metrics (including consultations and community site visits) for five years. Lois Johnson, general counsel, summarized hearing testimony, noting stakeholders raised concerns about pharmaceutical spending, workforce shortages and equity.
Commissioners voted by roll call to publish the final CMIR and to transmit the report to the Department of Public Health so that the DO approval can be reassessed if warranted; staff also recommended transmitting the report to the Attorney General for market monitoring. The vote begins a 30‑day period after which the parties may close their transaction, and staff said the DO program retains authority to require additional conditions or corrective investments if price growth is substantial.
The commission said it will use the reporting commitments and DO conditions to monitor price growth and access over the coming years and urged coordinated oversight across agencies as the project progresses.
